Warfare Reengineered
Genomics is currently being heavily utilized by the U.S. military across multiple domains, spanning soldier health, operational readiness, and long-term strategic planning. As genomic technologies mature, the Department of Defense (DoD) has increasingly treated them not only as medical tools, but as strategic assets capable of reshaping force sustainability, logistics, and national security economics.
One of the most immediate applications of genomics within the military is in enhancing medical outcomes for service members. Through agencies such as DARPA and the Defense Health Agency, the military funds research aimed at improving recovery time, resilience, and survivability in extreme environments. These efforts are often framed under DARPA’s guiding biomedical goals: “Optimize, Prevent, and Restore.” A notable example is DARPA’s Smart Red Blood Cells (RBCs) program, which sought to bioengineer human red blood cells to perform enhanced immune and sensing functions. The premise of the program was to create cells capable of responding dynamically to infection or injury, enabling faster recovery and improved battlefield survival (DARPA grant page).
From an economic perspective, programs like Smart RBCs illustrate how defense-funded genomics research subsidizes high-risk innovation that might otherwise be too costly for the private sector. The infrastructure, expertise, and intellectual property generated through these initiatives frequently spill over into civilian biotechnology, accelerating commercial advances in regenerative medicine, synthetic biology, and advanced therapeutics. Defense contracts often serve as early, non-dilutive funding sources for academic labs and biotech startups, reducing R&D risk and catalyzing private investment. In this way, military genomics programs do not exist in isolation; they help shape the broader biotech economy by seeding technologies that later enter healthcare markets.
At the same time, the military’s interest in genomics extends beyond defensive medicine into strategic threat assessment, particularly concerning gene editing technologies such as CRISPR-Cas systems. Although much of the discussion remains speculative, CRISPR has been formally identified as a potential national security concern due to its accessibility, scalability, and dual-use nature. In 2016, then–Director of National Intelligence James Clapper included gene editing technologies in the U.S. Intelligence Community’s Worldwide Threat Assessment, citing their potential for misuse in creating novel biological threats .
In response to these concerns, DARPA and other defense organizations have invested in biosecurity and counter-biotechnology programs, aimed at detection, attribution, and mitigation rather than offensive development. These efforts include early-warning biosurveillance systems, rapid vaccine platforms, and tools to identify genetically engineered organisms. Economically, this has fueled a growing biosecurity market, where companies develop diagnostics, sequencing platforms, and AI-driven surveillance tools that serve both military and civilian public health needs. The COVID-19 pandemic further reinforced the value of these systems, accelerating government procurement and long-term contracts that blur the line between defense and healthcare infrastructure.
Beyond direct threats to human health, genomics introduces the possibility of agricultural and ecological warfare, an area of increasing concern among security analysts. Rather than targeting populations directly, adversaries could hypothetically engineer pathogens or pests aimed at specific crops or keystone species. Such an approach could destabilize food supplies, disrupt trade, and induce economic collapse without immediate military confrontation. For example, targeted attacks on staple crops like wheat, rice, or corn—or on pollinators critical to agricultural productivity—could have cascading effects across global supply chains.
The economic implications of such a threat are profound. Agriculture is deeply intertwined with national security, employment, and geopolitical stability. A successful attack on a major crop system could inflate food prices, strain international trade relationships, and force governments to divert massive resources toward mitigation and recovery. As a result, military genomics increasingly overlaps with agricultural biotechnology, prompting investments in genetically resilient crops, pathogen-resistant livestock, and genomic monitoring of ecosystems. These efforts again stimulate commercial innovation, benefiting agritech firms while simultaneously raising ethical and regulatory questions about data ownership, genetic modification, and environmental risk.
Economic Implications: Defense Procurement and Venture Capital
The intersection of military genomics and economics is especially visible in venture capital flows and defense procurement strategies:
● Defense Procurement as Innovation Seed Funding. DoD programs often operate like venture investors for emerging biotech. Agencies such as DARPA, the Army Medical Research and Development Command, and the Air Force Office of Scientific Research issue Broad Agency Announcements (BAAs) that attract academic labs and commercial startups, fostering dual-use technologies spanning synthetic biology, genomic sequencing, and bioengineering. These procurements can validate early-stage firms, making them more attractive to institutional VC investors (NSF Interagency Synthetic Biology Working Group (SBWG)).
● Venture Capital and Commercial Spillover. Venture capital in genomics and life sciences has surged over the past decade, driven by breakthroughs in CRISPR, gene therapy, and high-throughput sequencing. According to market analyses, investments in genomics and synthetic biology startups have become a significant segment of life science venture capital, with companies developing tools such as sequencing platforms, bioinformatics software, and gene editing delivery systems drawing substantial funds. This VC ecosystem benefits indirectly from defense procurement, as military-funded breakthroughs de-risk technologies that later enter broad commercial markets, “the Defense Innovation Unit, a strategic sourcing organization for DoD, showed that for every $1 of prototype contract value awarded to a company, venture capitalists invest 10-20 times that amount in additional equity capital” (Mike Brown, Forbes). This illustrates how military investment de-risks technology investments and attracts commercial capital.
The economics of genomics is thus shaped by a feedback loop: government investment in strategic genomic R&D reduces technological uncertainty, attracting private capital and driving job creation, intellectual property formation, and downstream commercial products. In turn, a vibrant commercial genomics industry strengthens supply chains and expands the pool of technologies available for defense uses.
In sum, genomics occupies a uniquely dual-use position within the modern military ecosystem. It functions simultaneously as a tool for protecting soldiers, a domain of emerging security threats, and a powerful economic driver shaping biotechnology, healthcare, and agriculture. Defense investment in genomics lowers innovation barriers, accelerates commercialization, and influences market priorities, while also demanding new governance frameworks to manage risk, misuse, and long-term societal impact. As genomic technologies continue to advance, policymakers will face the challenge of balancing military preparedness and economic growth with ethical restraint and global stability.
